Skip to main content

Table 1 Patient characteristics

From: The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers

  SLE, active renal disease SLE, non-active renal disease Diabetic nepharopathy ANCA associated vasculitis
Number 19 79 74 11
Female/male, number 17/2 71/8 6/8 4/7
Age, years 31 (19 to 60) 44 (21 to 72) 58 (27 to 93) 63 (38 to 78)
SLEDAI 14 (11 to 23) 2 (0 to 10) na na
BVAS na na na 5 (0 to 16)
Immunosuppresive treatment 19 × Pred 7 × Cyc, 1 × Aza 13 × HCQ, 2 × MMF 62 × Pred, 20 × Aza, 37 × HcQ, 15 × MMF, 3 × MTX, 3 xBelim, 1 × Flebo 1 × Rtx 9 × Pred, 1 × Cyc, 6 × Aza, 2 x Rtx
Prednisolone dose, mg, median (IQR) 40 (30 to 50) 5.0 (5.0 to 7.5) - 5.0 (2.5 to 5.0)
  1. Values are mean (range) unless stated otherwise. Aza, azathioprine; Belim, belimumab; BVAS, Birmingham Vasculitis Activity Score; Cyc, pulse cyclophosphamide; HCQ, hydroxychloroquine; Flebo, flebogamma; MMF, mycophenolate mofetil; MTX, methotrexate; na, not applicable; Pred, prednisolone; Rtx, rituximab; SLE, systemic lupus erythematosus; SLEDAI, systemic lupus erythematosus disease activity index.
\